In briefBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7246.1358/b (Published 20 May 2000) Cite this as: BMJ 2000;320:1358
FDA backs Herceptin: The US Food and Drug Administration says that despite the recent findings that Genentech's breast cancer drug Herceptin (trastuzumab) was linked to the deaths of 15 patients and 47 adverse reactions, the drug's benefits still outweigh its risks.
Mobile phones might pose risk to children: The UK government is …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial